Browse Studies — Arctuva

Phase 2

A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a …

Medulloblastoma RecurrentEpendymoma RecurrentATRT Recurrent+1 more

Estimated

~$10 – $6,250

Medical University of ViennaNCT01356290

Phase 1

A Safety and Feasibility Study of NeuroNavigation-Guided Low Intensity Focused Ultrasound With Microbubbles to Enhance Nivolumab Delivery for the Treatment of Relapsed and Progressive Diffuse Midline Glioma and Other High Grade Brain Tumors

This is an open-label phase 1 safety and feasibility study evaluating a novel combination therapy for progressive and relapsed diffuse midline glioma (DMG) and…

Diffuse Midline Glioma or Diffuse Intrinsic Pontine GliomaHigh Grade GliomasMedulloblastoma Recurrent+3 more

Estimated

~$10 – $5,625

Children's National Research InstituteNCT07664176

Phase 1

JACOB: Joint Administration of cDNA for TP53, checkpOint Inhibition and Boost/Hypofractionated Radiation. A Phase 0/1 Study in Children With Recurrent, Progressive or Refractory CNS Malignancies.

This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come…

CNS MalignanciesMedulloblastoma RecurrentATRT Recurrent+4 more

Estimated

~$10 – $5,625

Children's National Research InstituteNCT07017816